StrainX Bioworks has emerged from stealth after raising $13 million in Series A funding, highlighting growing investor confidence in India’s synthetic biology and deep-biotech ecosystem.
Tech-enabled grab-and-go coffee chain Abcoffee has raised ₹61 crore in a pre-Series B funding round led by Kliff Ventures, with participation from existing investors. The startup, which operates a network of small-format coffee kiosks in high-footfall locations like metro stations, corporate parks, and college campuses, also reported doubling its revenue in FY26. Unlike traditional café chains that require large seating spaces and higher overheads, Abcoffee focuses on speed, affordability, and technology-driven operations — allowing customers to order via app or QR code and grab their coffee in under two minutes. The fresh capital will be used to expand to 200+ locations across India and invest in proprietary coffee brewing technology.
Ashish Kumar, the co-founder of Fundamentum Partnership, has just unveiled F2A (Fundamentum Frontier Advisors) — a massive ₹2,000 crore fund dedicated entirely to AI and deeptech startups. And as an anchor investor, he's brought in none other than Nandan Nilekani, the Infosys co-founder and one of India's most respected tech minds.
The patient is a 29‑year‑old man named Alex. Four years ago, a diving accident left him paralyzed from the neck down. He cannot move his arms or legs. He cannot feed himself. He breathes with a ventilator. But he can think. And thinking, it turns out, is enough. Implanted in his motor cortex is a coin‑sized device with 1,024 flexible electrodes, thinner than a human hair, each listening to the faint electrical chatter of his neurons. The device, from Elon Musk's Neuralink, transmits that chatter wirelessly to a small receiver on his chest, which relays it to a nearby computer. An AI model, trained on months of Alex's attempted movements, decodes his neural firing patterns into commands: move cursor up, click, type letter. Alex can now browse the web, send emails, play chess, and control a robotic arm. He does all of this with his thoughts alone.
The printer does not look like a medical miracle. It resembles a modified inkjet, about the size of a dormitory refrigerator, with six cartridges instead of four. But instead of cyan, magenta, yellow, and black, these cartridges contain living cells: hepatocytes (liver cells) from a donor, endothelial cells to line blood vessels, and a gelatin‑based bio‑ink that serves as a temporary scaffold. The print bed is chilled to 4°C to keep the cells viable. The print head moves in precise, programmed patterns, laying down layer after layer of cells, building a three‑dimensional structure that mirrors the complex geometry of a human liver segment. After six hours, the print is complete. The construct is transferred to a bioreactor, where it matures for two weeks, the cells knitting together, the scaffold degrading, and tiny blood vessels forming their own primitive networks. Then, the packaged organ—a 4‑centimeter cube of functional liver tissue—is rushed to the operating room.
The voice on the phone was unmistakable. It had the rasp of a lifetime of cigarettes, the soft Southern drawl that rounded off consonants, the particular rhythm of a woman who had told a million bedtime stories. "Baby, it's Grandma," the voice said. "I need you to listen carefully. I'm in trouble. I was driving home and there was an accident. I'm fine, but the other driver is hurt. The police say I need to post bail. I'm at the station. Can you send $5,000? I'll pay you back. Please, baby. Don't call anyone else. Just send it."
The coal plant has been running since 1972. Its boilers are scaled, its turbines worn, its air permits a constant battle. The town of Kemmerer grew up around it; the miners' homes, the union hall, the diner where shift workers eat breakfast at 3 PM. Coal is identity here. But coal is also dying. The plant's owner, PacifiCorp, plans to shutter it by 2030. Then, something unexpected happened. A different kind of power plant broke ground across the road. It will not have cooling towers or a smokestack. It will not burn anything. It will be smaller than the coal plant's parking lot. And it will employ half as many people, but those jobs will last decades longer, and the electricity will be cheaper, cleaner, and more reliable than anything coal ever produced.
The rows of photobioreactors stretch to the horizon, each a vertical glass tube twelve feet tall, filled with a vivid emerald liquid. The liquid is alive—dense with Chlamydomonas reinhardtii, a single‑celled green alga that has been genetically engineered to do something no natural plant can manage: absorb carbon dioxide from ambient air at a rate one hundred times faster than a tropical rainforest, then excrete long‑chain hydrocarbons that can be refined directly into gasoline, diesel, and jet fuel. The facility, operated by a startup called Algix, covers 200 acres of sun‑baked desert. It consumes no arable land, no fresh water (the algae grow in brackish groundwater), and no fertilizer (the nitrogen comes from the air). Its only inputs are sunlight, salt water, and the open air. Its outputs are fuel and oxygen.
Pantherun’s reported $220 million pipeline reflects broader conversations around deeptech, industrial partnerships and India’s evolving startup ambitions.
The lab is dark. No human has entered for three weeks. Inside, a collection of robotic arms, pipetting stations, and chemical sensors moves with quiet precision. A central AI—trained on millions of scientific papers and thousands of failed experiments—decides what to test next. It synthesizes a candidate molecule, purifies it, measures its properties, compares the results to its predictions, updates its internal model, and designs the next experiment. All night. All day. Without coffee, without distraction, without ego. In the past 72 hours, this self‑driving lab has performed 12,000 experiments—more than a human graduate student could complete in a decade. It has discovered three new organic light‑emitting materials, one of which outperforms the current industry standard by 15 percent.